Browsing by Author Buizen, L

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 3 of 3
Issue DateTitleAuthor(s)Citation
2016Opposite associations between alanine aminotransferase and γ-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) studyBuizen, L; Donoghoe, Mark William; Gebski, Val; George, Jacob; Januszewski, Andrzej Szczesny; Jenkins, Alicia; Keech, Anthony (Tony); Sullivan, David; Twigg, Stephen; Williams, Kathryn; Ehnholm, Christian P; Manning, Patrick; Nicholson, Geoff; O'Brien, Richard C; Tan, Yong Mong; Young, Simon; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Western Clinical School: Westmead Institute for Medical Res; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Central Clinical School: Medicine; Central Clinical School: MedicineOpposite associations between alanine aminotransferase and γ-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, Metabolism: Clinical and Experimental, vol.65, 5, 2016,pp 783-793
2017Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit StudyBuizen, L; King, Madeleine; O'Connell, Rachel; Roncolato, Felicia; Stockler, Martin; Aotani, Enriko; Avall-Lundqvist, Elisabeth; Berek, Jonathan; Berton-Rigaud, Dominique; Donnellan, Paul; Feeney, Amanda; Friedlander, M; Heitz, Florian; Hilpert, Felix; Joly, F; Lanceley, Anne; Okamoto, Aikou; Oza, Amit; Pignata, Sandro; NH&MRC Clinical Trials Centre; Psychology; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreReducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study, The Oncologist, vol.22, 9, 2017,pp 1117-1124
2015Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes studyBarter, Philip; Buizen, L; Januszewski, Andrzej Szczesny; Jenkins, Alicia; Keech, Anthony (Tony); O'Connell, Rachel; Ong, Kwok; Rye, Kerry-Anne; Sullivan, David; Scott, Russell; Taskinen, M; Xu, Aimin; Central Clinical School: Heart Research Institute; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Central Clinical School: Heart Research Institute; Central Clinical School: Heart Research Institute; NH&MRC Clinical Trials CentreRelationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study, Diabetologia, vol.59, 8, 2015,pp 2035-2044